GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith details of Earnings Call slated for Monday, May 27, 2024 at 08:30 a.m. to 09:30 a.m. (IST) for your information and record. GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
The trading window was closed from March 31, 2024 to May 26, 2024 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31, 2024. GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2024 And Recommending Dividend, If Any, On Equity Shares For The Year Ended March 31, 2024
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2024 and to consider and recommend dividend, if any, on Equity shares for the year ended March 31, 2024. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation of Securities Subscription & Shareholder''s Agreement and Power Purchase Agreement executed by the Company
Glenmark Pharma Gets USFDA Nod For Generic Anti-inflammatory Drug
Glenmark Therapeutics Inc, USA will distribute the drug in the US market, the drug maker said. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives ANDA approval for Acetaminophen and lbuproden Tablets GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
With reference to the subject mentioned above, kindly find enclosed rating rationale issued by India Ratings and Research for your reference.
Glenmark Recalls 6,528 Bottles Of Blood Pressure Drug In US
The affected lot has been produced in India and is being recalled by New Jersey-based Glenmark Pharmaceuticals Inc for 'failed dissolution specifications', the USFDA said. GLENMARK PHARMACEUTICALS LTD. - 532296 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company GLENMARK PHARMACEUTICALS LTD. 2 CIN NO. L24299MH1977PLC019982 3 Report filed for FY 2023-2024 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2021-22, 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-22, 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Harish KuberDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- V S Mani Designation : -Executive Director and Global Chief Financial Officer Date: 12/04/2024 GLENMARK PHARMACEUTICALS LTD. - 532296 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGLENMARK PHARMACEUTICALS LTD. 2CIN NO.L24299MH1977PLC019982 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harish Kuber Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: V S Mani Designation: Executive Director and Global Chief Financial Officer EmailId: [email protected] Date: 12/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.